Huang et al. focused on this CXCR4/SDF-1α interaction and found that the addition of a CXCR4 peptide antagonist to cytarabine, which is used in conventional chemotherapy in leukemia, has a synergistic effect on AML treatment. Here, CXCR4 is linked to acute myeloid leukemia.